-
Zogenix's Dravet Syndrome Treatment Returns 'Strong' Results
Friday, September 29, 2017 - 8:30am | 361Read More...Shares of Zogenix, Inc. (NASDAQ: ZGNX) traded higher by 200 percent early Friday morning after the company announced top-line results from a phase 3 clinical trial exploring its drug called ZX008 for the treatment of Dravet syndrome. Zogenix said that its trial met its primary objective of...
-
ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM)
Monday, June 24, 2013 - 3:16pm | 935Read More...Oppenheimer has a new team of analysts focused on biotechnology and specialty pharmaceuticals. And, research from the new team includes recommendations to buy shares of Antares Pharma (NASDAQ: ATRS), Intercept Pharmaceuticals (NASDAQ: ICPT), Questcor Pharmaceuticals (NASDAQ: QCOR) and ViroPharma...
-
Oppenheimer Adjusts ZGNX EPS Estimates
Friday, March 4, 2011 - 9:19am | 61Read More...Oppenheimer is adjusting its Zogenix, Inc.'s (NASDAQ: ZGNX) estimates. “We anticipate ZGNX's $49.1M in cash as of 12/31, will sustain operations into 4Q11, suggesting an equity offering or other fund raising is likely by 2H11,” Oppenheimer writes. “We adjust our 2011 EPS estimate to ($1.36) from ($...
-
Wells Fargo Initiates Coverage Of Zogenix With An OP Rating
Monday, January 3, 2011 - 11:56am | 89Read More...Wells Fargo is initiating coverage of Zogenix, Inc. (NASDAQ: ZGNX) with an Outperform rating. “We believe continued Rx growth of Sumavel DosePro and clinical news flow of ZX002 could drive share price performance in the next 6-12 months,” Wells Fargo writes. “Expect sustainable profitability by...
